Skip to main content
. Author manuscript; available in PMC: 2019 Oct 1.
Published in final edited form as: Urol Oncol. 2014 May 16;32(5):637–644. doi: 10.1016/j.urolonc.2013.12.012

Table 2.

Chemotherapy regimens: “If you use any of the following neoadjuvant chemotherapy regimens, please specify the number of cycles used. Indicate all that apply”

Chemotherapy regimen Respondents
(n = 63)		 The most commonly
used number of cycles
(n, %)
Gemcitabine/cisplatin D1, 8 of 21-d cycle 56 (89%) 4 cycles (40, 63%)
Gemcitabine/carboplatin 23 (37%) 4 cycles (14, 22%)
Gemcitabine/cisplatin D1, 8, 15 of 28-d cycle 20 (32%) 3 cycles (12, 19%)
MVAC 18 (29%) 3 cycles (12, 19%)
Dose-dense MVAC 12 (19%) 4 cycles (10, 16%)
Gemcitabine/single agent 6 (10%) 6 cycles (3, 5%)
Other (carboplatin/paclitaxel) 2 (4%) 3 cycles (2, 3%)